Search
Eupraxia Pharmaceuticals Inc
EPRXAdd to Watchlist
6.690USD
-0.020-0.30%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
413.50MMarket Cap
LossP/E TTM
More Details of Eupraxia Pharmaceuticals Inc Company
Eupraxia Pharmaceuticals Inc. is a clinical-stage biotechnology company. The Company is focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. DiffuSphere, a proprietary, polymer-based micro-sphere technology, is designed to facilitate targeted drug delivery of both existing and novel drugs. The Company’s EP-104GI is in a Phase Ib/IIa trial, the RESOLVE trial, for the treatment of eosinophilic esophagitis (EoE). EP-104GI is administered as an injection into the esophageal wall, providing local delivery of drug. The Company also completed a Phase IIb clinical trial (SPRINGBOARD) of EP-104IAR for the treatment of pain due to knee osteoarthritis. In addition, the Company is developing a pipeline of later and earlier-stage long-acting formulations. Its potential pipeline indications include candidates for other inflammatory joint indications and oncology.
Eupraxia Pharmaceuticals Inc Info
Ticker SymbolEPRX
Company nameEupraxia Pharmaceuticals Inc
IPO dateMar 09, 2021
CEOHelliwell (James A)
Number of employees33
Security typeOrdinary Share
Fiscal year-endMar 09
Address201-2067 Cadboro Bay Rd.
CityVICTORIA
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryCanada
Postal codeV8R 5G4
Phone12505903968
Websitehttps://eupraxiapharma.com/home/default.aspx
Ticker SymbolEPRX
IPO dateMar 09, 2021
CEOHelliwell (James A)
Company Executives of Eupraxia Pharmaceuticals Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Michael Wilmink, M.D.
Dr. Michael Wilmink, M.D.
Independent Director
Independent Director
228.23K
+1.47%
Richard M. Glickman ,
Richard M. Glickman ,
Independent Director
Independent Director
18.86K
+13.07%
Dr. James A. Helliwell, M.D.
Dr. James A. Helliwell, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Dr. Simon Pimstone, M.D., Ph.D.
Dr. Simon Pimstone, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Paul Geyer
Mr. Paul Geyer
Independent Director
Independent Director
--
--
Mr. John S. Montalbano
Mr. John S. Montalbano
Independent Director
Independent Director
--
--
Dr. Amanda Malone
Dr. Amanda Malone
Chief Operating and Scientific Officer
Chief Operating and Scientific Officer
--
--
Mr. Alexander Rothwell
Mr. Alexander Rothwell
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Adam Peeler
Mr. Adam Peeler
Investor relations
Investor relations
--
--
Mr. Paul A. Brennan
Mr. Paul A. Brennan
Chief Business Officer
Chief Business Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Michael Wilmink, M.D.
Dr. Michael Wilmink, M.D.
Independent Director
Independent Director
228.23K
+1.47%
Richard M. Glickman ,
Richard M. Glickman ,
Independent Director
Independent Director
18.86K
+13.07%
Dr. James A. Helliwell, M.D.
Dr. James A. Helliwell, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Dr. Simon Pimstone, M.D., Ph.D.
Dr. Simon Pimstone, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Paul Geyer
Mr. Paul Geyer
Independent Director
Independent Director
--
--
Mr. John S. Montalbano
Mr. John S. Montalbano
Independent Director
Independent Director
--
--
FAQs
Who are the top five shareholders of Eupraxia Pharmaceuticals Inc?
The top five shareholders of Eupraxia Pharmaceuticals Inc are: Dr. Michael Wilmink, M.D.
How many institutions hold shares of Eupraxia Pharmaceuticals Inc (EPRX)?
As of 2026Q1, 56 institutions hold shares of Eupraxia Pharmaceuticals Inc, with a combined market value of approximately 19.60M, accounting for 32.43% of the total shares. Compared to 2025Q4, institutional shareholding has increased by 818141.00.